BIOTESYS unterstützt bei Publikationen und VERÖFFENTLICHT selbst regelmässig wissenschaftliche Artikel zu unterschiedlichen Themen
Lesen Sie hier unsere Publikationen aus dem Umfeld der Prüfung und wissenschaftlichen Absicherung von biologischen und chemischen Produkten.
Unsere
Publikationen
Using mid infrared technology as new method for the determination of the dwell time of salivary substitutes on three dimensional gingiva models
Many people suffer from dry mouth (xerostomia) due to radiotherapy treatment of head and neck cancer, diseases like Sjogren’s syndrome or as adverse effects to prescribed medications. Salivary substitute products like gels or sprays are often used for treatment. Efficacy of those oral care products are regularly assessed by validated or even not validated questionnaires. To determine the adhesion effect over time more objectively a new and sensitive method was established. The following study was designed to assess the dwell time of different oral care products in vitro.
Engelhart K, Popescu A, and Bernhardt J
BMC Ear Nose Throat Disord. 2016; 16: 6. Published online 2016 Mar 15. doi: 10.1186/s12901-016-0025-5
vollständige Publikation lesenIn Vitro Activation of eNOS by Mangifera indica (Careless™) and Determination of an Effective Dosage in a Randomized, Double-Blind, Human Pilot Study on Microcirculation.
Mangifera indica fruit preparation (Careless™) activates the evolutionary conserved metabolic sensors sirtuin 1 and adenosine monophosphate-activated protein kinase, which have been identified as playing a key role in microcirculation and endothelial function. Here, an acute effect of a single dose of 100 mg or 300 mg Careless™ on microcirculation was investigated in a randomized, double-blind, crossover pilot study in ten healthy women to determine the effective dosage.
Gerstgrasser A, Röchter S, Dressler D, Schön C, Reule C, Buchwald-Werner S
Planta Med. 2016 Mar;82(4):298-304. doi: 10.1055/s-0035-1558219. Epub 2015 Nov 19.
vollständige Publikation lesenQuality control data of physiological and immunological biomarkers measured in serum and plasma.
In two work packages of the MARK-AGE project, 37 immunological and physiological biomarkers were measured in 3637 serum, plasma or blood samples in five batches during a period of 4 years. The quality of the serum and plasma samples was very good as judged by the low number of biomarker measurements (only 0.2%) that were rejected because of a high hemolysis, icteria or lipemia of the samples. Using quality control samples, day-to-day and batch variations were determined. The mean inter-assay variation of the five batches were all below 8%, with an average inter-assay coefficient of variation of all biomarkers of 4.0%.
Jansen E, Beekhof P, Cremers J, Weinberger B, Fiegl S, Toussaint O, Bernhard J, Gonos E, Capri M, Franceschi C, Sikora E, Moreno-Villanueva M, Breusing N, Grune T, Bürkle A, Dollé ME.
Mech Ageing Dev. 2015 Nov;151:54-9. doi: 10.1016/j.mad.2015.06.004. Epub 2015 Jul 9. PMID: 26166476
vollständige Publikation lesenJoint health: What degree of evidence is necessary to support health claims for food supplements, taking glucosamine as an example?
Arthropathies present a major challenge for the public health system, both in terms of epidemiology and health economics, particularly against the background of demographic changes in the Western world. Much attention must be paid to prevention, because of the limited options and high technical and financial expenditure with respect to treatment. Among other factors, nutrition plays an important role.
Jürgen Bernhardt, Christof Jaenicke, Peter Prock, Ulrich Schneider
vollständige Publikation lesenWissenschaftliche Absicherung von Health Claims. Eine Bestandsaufnahme
Mit der VO (EG) Nr. 1924/2006 über nährwert- und gesundheitsbezogene Angaben über Lebensmittel (sog. „Health Claims Verordnung“ – HCV) wird Lebensmittelunternehmen die Möglichkeit eröffnet, Lebensmittel mit einer wirkbezogenen Aussage zu vermarkten. Acht Jahre nach dem Inkrafttreten der Verordnung sollen in der gebotenen Kürze regulatorische Entwicklungen in der Umsetzung der HCV nachvollzogen und Informationen zur Vorgehensweise bei der Zulassung von Health Claims gegeben werden. Darüber hinaus wird auf die Anforderungen an eine wissenschaftliche Absicherung von gesundheitsbezogenen Angaben und die dafür notwendigen Evidenzkriterien eingegangen. Von der EFSA wurden hohe Hürden für die wissenschaftliche Absicherung aufgestellt. Mit dem Artikel sollen Schwächen bei der bisherigen Vorgehensweise dargestellt werden, ein Überblick über die noch offenen Themen gegeben und Möglichkeiten zur Bewältigung der wissenschaftlichen Anforderungen aufgezeigt werden.
Kügel JW, Schön C
pharmind 2015, No. 5 page 710
vollständige Publikation lesenMARK-AGE population: From the human model to new insights
Many relevant EU projects were funded during last decade and MARK-AGE (European Study to Establish Biomarkers of Human Ageing) was the first focused on the identification of biomarkers connecting itself with a previous funded project, i.e. GEHA (Genetic of Healthy Ageing) that identified European families with longevity component (Franceschi et al., 2007). MARK-AGE was mainly a cross sectional study, based on definite assumptions and focused on an age range between 34 and 75 years, in order to identify early biomarkers of biological vs. chronological age, potentially capable of predicting the rate of ageing later in life.
Miriam Capri, María Moreno-Villanueva, Elisa Cevenini, Elisa Pini, Maria Scurti, Vincenzo Borelli, Maria Giustina Palmas, Marco Zolid, Christiane Schön, Anne Siepelmeyer, Jürgen Bernhardt, Simone Fiegl, Gerben Zondag, Anton J.M. de Craen, Antti Hervonen, Mikko Hurme, Ewa Sikora, Efstathios S. Gonos, Claudio Franceschi
vollständige Publikation lesenGARANTIERT WIRKSAM UND UNBEDENKLICH: DIE KONTAKTAUFNAHME
Wir sind für Sie da – und zögern Sie nicht, uns mit einer spezifischen Fragestellung herauszufordern.
